• Weight Change at 3 months [ Time Frame: baseline and 3 months ]
  Measured in kilograms
• Gut microbiota composition [ Time Frame: 3 months ]
  Gut microbiota composition is assessed by 16S rRNA pyrosequencing. This analysis allows to obtain the relative abundance (%) of the different bacterial taxa and OTUs (operational taxonomic units).

• Change in waist circumference [ Time Frame: baseline and 3 months ]
  Measured in cm
• Change in systolic blood pressure [ Time Frame: baseline and 3 months ]
  Measured in mmHg
• Change in diastolic blood pressure [ Time Frame: baseline and 3 months ]
  Measured in mmHg
• Change in HbA1c [ Time Frame: baseline and 3 months ]
  Measured in %
• Change in plasma glucose [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in insulin [ Time Frame: baseline and 3 months ]
  Measured in μU/ml
• Change in lipids-total cholesterol [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in lipids-low density lipoprotein cholesterol [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in lipids-high density lipoprotein cholesterol [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in lipids-triglycerides [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in lipids-free fatty acids [ Time Frame: baseline and 3 months ]
  Measured in μmol/l
• Change in Uric Acid [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in interleukin-10 [ Time Frame: baseline and 3 months ]
  Measured in mmol/l
• Change in tumor necrosis factor [ Time Frame: baseline and 3 months ]
  Measured in mmol/l

• Drug: Benaglutide
  The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
  Other Name: rhGLP-1(7-36)
• Drug: Liraglutide
  The treatment of Liraglutide lasted three months.During the first week: 0.6mg per day;During the second week: 1.2mg per day; From third week onwards, 1.8mg per day.
  Other Name: Victoza

• Experimental: Benaglutide
  Benaglutide will be administered three times a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given 10 minutes before each meal.
  Intervention: Drug: Benaglutide
• Active Comparator: Liraglutide
  Liraglutide will be administered once a day by subcutaneous injection (under the skin) in the abdomen, thigh, or upper arm. It will be given independently of meals and preferably at the same each day.
  Intervention: Drug: Liraglutide

Inclusion Criteria:

1. Patients aged 18 to 65 years (to the date of screening)；
2. The newly diagnosed obese patients (BMI greater than 28 kg/m2) or abdominal obesity (male waist circumference is greater than 90cm, female waist is greater than 85cm).
3. Nearly a month have not used weight-related drugs,including various weight-loss drugs,GLP-1 analogs or agonists,metformin, acarbose,insulin,anti hyperthyroid drugs,etc;Or recently used weight-related drugs but the stable dose was more than 1 month,and the drug dose remained constant or decreased during the trial.
4. Weight stable for more than 3 months (weight fluctuations <5%).

Exclusion Criteria:

1. pregnant female.
2. Secondary diseases caused by other diseases: including hypothyroidism, increased cortisol, hypothalamic and pituitary lesions caused by obesity, all kinds of drug-induced obesity, and others.
3. Severe cardiovascular and cerebrovascular diseases (heart failure, myocardial infarction, acute hemorrhagic or ischemic encephalopathy), pulmonary heart disease or pulmonary insufficiency, renal failure, severe hepatitis.
4. Combined with acute complications of diabetes such as ketoacidosis, lactic acidosis, hyperosmolar state of diabetes.
5. Nearly a month had surgery, trauma, infection and so on.
6. Limb deformity incomplete, difficult to accurately determine the height, weight and other physical indicators.
7. Poor medication compliance or serious side effects (severe rash, syncope, etc.).